This is how exposed European Big Pharma is to the U.S.

This is how exposed European Big Pharma is to the U.S.

U.S. pricing has been the biggest issue of the year for drugmakers heavily exposed to the U.S. market.

This is how exposed European Big Pharma is to the U.S.

TL;DR

U.S. pricing has been identified as the most significant issue for drugmakers this year.
Companies heavily exposed to the U.S. market are particularly affected.
Pricing challenges in the U.S. market are a primary concern for pharmaceutical companies.

Continue lendo o artigo original